Dr. Eytan Stein is the Chief of the Leukemia Service, hematologic oncologist and clinical researcher at Memorial Sloan Kettering Cancer Center, with over 15 years’ experience in early-stage drug development and precision medicine approaches for blood cancers. He led the pivotal clinical trial demonstrating that revumenib, a menin inhibitor, was effective in patients whose cancers harbored molecular mutations commonly found in AML, work that helped establish menin inhibition as one of the most promising new therapeutic directions in the field.